Friday August 16, 2013 0 commentsCENTENNIAL - AlloSource, one of the nation's largest nonprofit providers of skin, bone and soft tissue allografts for surgical procedures and the world's largest processor of cellular bone allografts, announced the launch of a new proprietary allograft called AlloMend Acellular Dermal Matrix.
The new allograft can be used in a broad range of soft tissue surgical procedures, AlloSource said, including ventral hernia repair and post-mastectomy reconstruction.
AlloMend ADM is created through a proprietary process in which viable cellular elements that are capable of triggering an immune system response are removed from donated human skin, leaving a collagen elastin matrix behind, the company said.
Upon transplantation, the recipient's own cells infiltrate and repopulate this three-dimensional scaffold to begin the revascularization and remodeling process.
"We are dedicated to finding new ways to maximize the gift of life from generous tissue donors and courageous donor families," said Thomas Cycyota, AlloSource president and CEO.
"AlloMend is the latest allograft in a history of progressive innovations from AlloSource, and we look forward to it bringing the benefits of regenerative medicine to more patients in need."
The product is processed with an exclusive tissue-cleaning process without the use of detergents or enzymes, leaving no harmful residuals in the tissue, AlloSource said.
For more information, visit www.allosource.org.